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ABSTRACT
X-linked juvenile retinoschisis is a heritable con-
dition of the retina in males caused by mutations
in the RS1 gene. Still, the cellular function and
retina-specific expression of RS1 are poorly under-
stood. To address the latter issue, we characterized
the minimal promoter driving expression of RS1
in the retina. Binding site prediction, site-directed
mutagenesis, and reporter assays suggest an
essential role of two nearby cone-rod homeobox
(CRX)-responsive elements (CRE) in the proximal
2177/+32 RS1 promoter. Chromatin immunoprecipi-
tation associates the RS1 promoter in vivo with
CRX, the coactivators CBP, P300, GCN5 and acety-
lated histone H3. Transgenic Xenopus laevis expres-
sing a green fluorescent protein (GFP) reporter
under the control of RS1 promoter sequences
show that the 2177/+32 fragment drives GFP
expression in photoreceptors and bipolar cells.
Mutating either of the two conserved CRX binding
sites results in strongly decreased RS1 expression.
Despite the presence of sequence motifs in the pro-
moter, NRL and NR2E3 appear not to be essential
for RS1 expression. Together, our in vitro and in vivo
results indicate that two CRE sites in the minimal
RS1 promoter region control retinal RS1 expression
and establish CRX as a key factor driving this
expression.
INTRODUCTION
X-linked juvenile retinoschisis (RS) is a degenerative
disorder of the retina characterized by a splitting of the
inner retinal layers which eventually leads to visual
impairment (1). It is a common condition of juvenile
macular degeneration in males caused by mutations in
the retina-speciﬁc RS1 gene (2). The encoded protein,
termed retinoschisin, is secreted as a disulﬁde-linked
homo-oligomeric complex and is primarily localized on
the outer surface of the inner segments of cones and
rods as well as the outer nuclear and outer plexiform
layers of the retina (3–7). A main feature of the protein
is its highly conserved discoidin domain functionally
implicating retinoschisin in cell–cell interactions (2,5,8).
A recent study demonstrates that RS1 binding to the sur-
face of photoreceptors and bipolar cells is mediated
through its interaction with Na/K ATPase (9). To date,
there is no medical treatment for the condition, although
therapeutic gene delivery may be an option in the future
(10–13).
High mRNA levels of RS1 are present in the retina
as shown by northern blot hybridization to a number of
human (2) and mouse (14) tissues. Furthermore, in situ
hybridization experiments revealed RS1 transcripts in
rod and cone photoreceptor inner segments (3,15) and
also in other cell bodies of the retinal layers, namely in
bipolar cells, amacrine cells, and retinal ganglion cells (16).
In postnatal eye development of the mouse, measurable
levels of RS1 expression appear around postnatal day 1
(P1) and reach a maximum between P5 and P7. This level
of expression is then maintained throughout adult life,
indicating that continued de novo synthesis of RS1 is
required and is essential for the maintenance of retinal
integrity. The pineal gland is the only site of RS1 expres-
sion outside the eye (17). However, RS1/Y mice lacking
retinoschisin reveal no evidence of morphological changes
in the pineal gland, indicating that RS1 might have diﬀer-
ent functions in the pineal gland and the retina (17).
The molecular basis underlying retina-speciﬁc expres-
sion of RS1 is unknown so far, although knowledge
about regulatory sequences at the RS1 locus might lead
to designing novel tools for gene therapy ensuring targeted
and eﬃcient expression of the protein. Furthermore, the
functional importance of promoter variants in patients
lacking classical RS1 mutations or patients with highly
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variable RS phenotypes could be evaluated on the basis
of such data.
Preliminary evidence for a potential role of the tran-
scription factors cone-rod homeobox (CRX) and neural
retina leucine zipper protein (NRL) in retinal expression
of RS1 comes from its diﬀerential expression in mice
deﬁcient for CRX (18) and NRL (19). Recent genome-
wide expression proﬁling and chromatin immunopre-
cipitation (ChIP) approaches have revealed complex
retinal regulatory networks balanced by CRX and NRL
and the orphan nuclear receptor NR2E3 (18,20–23).
CRX is a nuclear protein critical for general photore-
ceptor maturation in both rods and cones (24,25), while
NR2E3 and NRL have speciﬁc roles in rod photorecep-
tor maturation and suppression of cone proliferation
(19,26,27). Mutations of any one of the three transcription
factors or the DNA binding sites in their respective pro-
moters lead to retinal pathology, most notably cone-rod
dystrophy (28), enhanced S-cone syndrome (29) and auto-
somal dominant retinitis pigmentosa (30).
To determine whether CRX, NRL and NR2E2 have a
direct regulatory eﬀect on human RS1 gene expression, we
characterized the cis-elements of the RS1 promoter with
special emphasis on these three factors. Using a compu-
tational approach to predict regulatory sequences, we
identiﬁed multiple putative cis-elements in the RS1 prox-
imal promoter, including three evolutionarily conserved
sites for CRX. We deﬁned the exact binding sequences
for CRX and demonstrated CRX-dependent regulation
of the 177/+32 promoter region driving RS1 expression
in vitro and in vivo.
MATERIALS AND METHODS
Bioinformatic analyses
RS1 promoter sequences from diﬀerent species were
retrieved with Gene2Promoter (Genomatix GmbH,
Munich, Germany) and DataBase of Transcriptional
Start Sites (dbtss; http://dbtss.hgc.jp). The upstream regu-
latory regions were analyzed for putative transcription
factor binding sites by Matinspector (Genomatix GmbH)
with the matrices V$CRX.01 (CRX), V$NRL.01 (NRL)
and V$PNR.01 (NR2E3). Only matrices predicted with
a core similarity of 1.0 and a matrix similarity >0.75
were included in the analysis. The computer algorithm
NUBIScan (31) and a self-deﬁned matrix based on
known NRL and NR2E3 target genes was used to predict
DNA recognition sites for both nuclear receptors.
Transcription start sites of the human and mouse RS1
genes have been determined previously (14).
Promoter and expression constructs
RS1 promoter fragments were cloned into the KpnI/
HindIII site of the luciferase reporter vector pGL4.10
(Promega, Madison, WI, USA). Three fragments, starting
from 703, 419 and 177 and ending at +32, respec-
tively, relative to the transcriptional start site were gener-
ated by PCR from human genomic DNA with KpnI- and
HindIII-ﬂanked oligonucleotide primers (Supplementary
Table 1). Mutant and deletion promoter constructs were
based on the wild-type KpnI177/HindIII+32 promoter
fragment: mutated promoter fragments, termed mCRE1,
mCRE3 and mCRE13, were cloned by site-directed muta-
genesis (QuikChange Multi Site-Directed Mutagenesis
Kit, Stratagene, La Jolla, CA, USA) with primers replac-
ing the central conserved nucleotides of the CRX binding
site (Supplementary Table 2). The mCRE2 mutant was
generated by cloning two PCR fragments overlapping
the CRX-responsive element (CRE) motif with an ApaI
restriction site. Similarly, double mutants mCRE12,
mCRE23 and the triple mutant mCRE123 were generated
with mutated plasmid templates for the PCR (Supple-
mentary Table 3). Sequences of cloned fragments are
listed in Supplementary Table 4.
The NR2E3 binding site deletion fragment was
produced by cloning two PCR fragments with EcoRI
sequences at each of the 30-ends (Supplementary
Table 5). The NRE deletion fragment was generated in
two steps. An EcoRI restriction site was cloned to replace
the last six base pairs of the NRE fragment at nucleotide
80, so that the NRE site was ﬂanked by an artiﬁcial
EcoRI and an endogenous HpaI restriction site, through
which NRE was removed (Supplementary Table 6).
Full-length NR2E3 and OTX2 were ampliﬁed from
human retinal cDNA and cloned into the mammalian
expression vector pcDNA3.1 (Invitrogen, Carlsbad, CA,
USA). The construction of CRX and NRL expression
vectors has been reported previously (26). For Xenopus
laevis transgene vectors, promoter fragments were cloned
into Xop0.8-eGFP-N1 to replace the X. laevis opsin pro-
moter. For veriﬁcation, all cloned constructs were directly
sequenced by capillary sequencing (Applied Biosystems,
Darmstadt, Germany).
Cell culture and luciferase assays
Y79 retinoblastoma cells were maintained in DMEM con-
taining 10%FCS and 100U/ml penicillin/streptomycin.
HEK293 cells were grown in DMEM medium as stated
above, and supplemented with 500 mg/ml G418. BV-2
microglia cells were cultured as described previously (32).
All cells were grown in a 378C incubator with a 5% CO2
environment. For transfections, 1 million Y79 or 500 000
HEK cells were seeded overnight into 6-well plates. Y79
cells were then transfected with FugeneHD (Roche
Applied Science, Mannheim, Germany), following the
manufacturer’s instructions. HEK293 cells were trans-
fected using the standard calcium–phosphate method.
Brieﬂy, cells were transfected at 80% conﬂuence with up
to 7 mg of DNA in 218 ml of CaCl2 and 2 BBS buﬀer
(50mM BES, 280mM NaCl, 1.5mM Na2HPO4). After
48 h, cells were harvested and lyzed in Lysis Buﬀer
(Promega). For luciferase assay, 20 ml of cytosolic extract
and 100 ml of assay reagent were used. Light emission was
measured with a FluoStar Optima (BMG LABTECH
GmbH, Oﬀenburg, Germany). Luciferase activity was
normalized to the protein content of each well by dividing
the measured relative light units by the protein concen-
tration measured by Bradford assay. Each experiment
was performed at least three times in duplicate wells.
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Electrophoretic mobility shift assay
Electrophoretic mobility shift assay (EMSA) experiments
were performed with nuclear extracts from Y79 cells,
mouse retina, BV-2 cells and in vitro translated proteins.
Oligonucleotides were designed based on the human RS1
promoter sequence. Nuclear extracts were prepared with
NE-PER Nuclear and Cytoplasmic Extraction Reagents
(Pierce, Rockford, IL, USA) and in vitro translated pro-
teins were prepared with the TnT Quick-Coupled in vitro
Transcription/Translation System (Promega, Mannheim,
Germany). Double-stranded oligonucleotides were
labeled with 32P-ATP and T4 polynucleotide kinase
(Roche Biochemicals, Mannheim, Germany). Radio-
labeled double-stranded oligonucleotides were incubated
with 5 mg of nuclear extract or 4 ml of translated proteins
and poly(dI-dC) in GSA binding buﬀer (Promega) for
20min at room temperature. In competition experiments,
unlabeled wild-type, mutant or consensus sequences as
well as anti-CRX antibody were included in the binding
reaction. Samples were loaded on a nondenaturing acry-
lamide gel in 0.5 TBE buﬀer and electrophoretically
separated for 1.5 h at 250V. Subsequently, gels were
dried and audioradiographed.
ChIP assay
ChIP assays were performed in human retinoblastoma
Y79 cells or Y79 cells transfected with CRX, NR2E3
and NRL as described previously (33). Brieﬂy, 10 million
cells were treated with 1% formaldehyde for 15min and
lyzed with SDS, Empigen and NP-40 (supplemented with
1mM PMSF, 1 mg/ml aprotinin and 1 mg/ml pepstatin A).
The nuclear pellet was homogenized by sonication twice
at 30% amplitude for 10 s. Immunoprecipitation was
performed on the lysate with 2.5 mg of anti-CRX antibody
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-
NR2E3 antibody (Santa Cruz Biotechnology), anti-NRL
antibody (Santa Cruz Biotechnology), anti-di-acetylated
(K9 and K14) histone H3 (Upstate Biotechnology, Lake
Placid, NY, USA), anti-p300 clone RW128 (Upstate
Biotechnology), anti-CBP (Upstate Biotechnology),
anti-Gcn5 (Santa Cruz Biotechnology) or anti-IgG anti-
body (Santa Cruz Biotechnology). After washing and
elution steps, cross-links were reversed at 658C overnight.
The immunoprecipitated DNA was puriﬁed using the
QIAquick PCR puriﬁcation kit (Qiagen, Hilden,
Germany) and analyzed by PCR using the speciﬁc for-
ward primer 50-CTT CCT CGC GAA CTG AAT CT-30
and reverse primer 50-TGC AAT GAA TGT CAA TGG
TT-30 for the RS1 promoter fragment 177/+130 and
the forward primer 50-TGC ACA TGA TGC CTA GTT
GC-30 and reverse primer 50-GAA GCA ATG GAG GGA
GAG AAC-30 for the RS1 promoter region 703/530.
Primers for the red-cone opsin promoter were used as
positive controls and have been described previously (34).
Real-time quantitative RT–PCR
RNA was extracted from retinae of both wild-type
C57/BL mice and Nrl/ mice with RNeasy Plus Mini
kit (Qiagen, Hilden, Germany). A total of 2.5mg RNA
was reverse transcribed into cDNA. Real-time quantita-
tive RT–PCR was performed in triplicate with an Icycler
(Biorad, Munich, Germany) in the presence of SYBR
green dye. The signal from a pair of primers (50-TCC
AGA ATG CCC ATA TCA CA-30 and 50-GCA CAC
CCA AAA CCT TGA CT-30) amplifying a RS1 cDNA
fragment was normalized by the HPRT signal from
primers (50-CAA ACT TTG CTT TCC CTG GT-30 and
50-CAA GGG CAT ATC CAA CAA CA -30).
Generation of transgenicX. laevis, immunolabeling
and confocal microscopy
Transgenic X. laevis were generated using the method
described by Kroll and Amaya (35) with modiﬁcations
(36). For each transgenesis, one sperm donor and three
egg donors were used. Embryos were housed in 4 l tanks
in an 188C incubator on a 12 h light/dark cycle. After 24 h,
embryos were exposed to 18 mg/ml G418 for 120 h (37).
Only developmentally normal animals were used in our
analysis; animals that were abnormally small or had
other developmental abnormalities were not used. Tad-
poles were initially screened for GFP expression and loca-
lization using an epi-ﬂuorescence microscope. Eyes from
representative tadpoles were cryosectioned and examined
by confocal microscopy 14 days postfertilization. Sections
were stained with wheat germ agglutinin, which labeled
the glycosylate membrane, and Hoechst 33342, which
stained nuclei.
RESULTS
Identification and analysis of putative binding sites
in the RS1 promoter
We have previously characterized the human and mouse
RS1 genomic regions and experimentally deﬁned the
transcription start sites (14). Based on DNA-microarray
expression data (18,19) and an in silico transcriptional
network (38), we hypothesized that RS1 might be a
direct target for transcription factors CRX, NRL and
NR2E3. We therefore used a bioinformatic approach to
predict evolutionarily conserved binding motifs for the
three transcription factors in the putative human RS1
promoter sequences. Within the ﬁrst 100-bp upstream of
the major transcription start site in human, dog and
mouse, comparative genomics locates three putative
CRE at 26/23, 47/44, and 58/55, as well as a
putative NR2E3 binding motif (76/62) and an NRL
response element (NRE, 99/81) (Figure 1A). Further
analysis revealed an ALU-repeat spanning the region
188/499 and binding sites for c-Ets-1 (729/714;
624/615), USF (700/695) and ELP (612/603)
(Figure 1B).
Since repetitive sequences are rarely located in regula-
tory regions, we speculated that the RS1 core promoter
is located downstream from the ALU-repeat. To further
delineate this region, we transfected three diﬀerent RS1
luciferase reporter constructs (703/+32, 419/+32
and 177/+32) into human Y79 retinoblastoma cells
which express endogenous RS1 transcripts. As a positive
control, we used the pGL3-300 PDE6A (cyclic-GMP
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speciﬁc phosphodiesterase 6A a subunit) promoter region,
which was shown to be transcriptionally active in Y79 cells
(39). The longest RS1 promoter construct (703/+32)
showed a basal level of luciferase expression similar to
the PDE6A promoter. When shortening the promoter to
419/+32 and further to 177/+32 the promoter activity
was retained, indicating that critical core promoter
sequences reside within the 177/+32 region (Figure 1C).
CRX strongly induces the RS1 proximal promoter
Having identiﬁed conserved transcription factor binding
sites in the 177/+32 sequence, we evaluated the indi-
vidual eﬀects of transcription factor candidates poten-
tially regulating the RS1 promoter via these sites. We
analyzed the transactivation potential of CRX, its
related family member OTX2, NRL and NR2E3 on the
Figure 1. Analysis of conserved transcription factor binding sites in the RS1 promoter and delineation of the proximal region. (A) Sequence
alignment of the putative RS1 promoter regions from human, dog and mouse. Conserved sequences are highlighted in gray and canonical binding
sites for CRX (CRE1 to 3), NR2E3 and NRL (NRE) are boxed. (B) DNA sequence of the putative human RS1 promoter. Potential cis-elements
are indicated. An interspersed ALU repeat is italicized. (C) Basal activity of three RS1 promoter–luciferase constructs (703/+32, 419/+32,
177/+32) and of a PDE6A positive control (300) transfected into Y79 retinoblastoma cells. RS1 promoter activities are comparable to the
PDE6A promoter, which is known to be active in Y79 cells. A schematic of the RS1 promoter is shown with transcription factor binding sites
and the ALU repeat (box). Each transfection was repeated three times with duplicate wells analyzed. Error bars represent the standard deviation of
the mean from protein normalized luciferase activities.
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promoter region. Transcription factor expression vectors
for the four nuclear proteins were cotransfected with the
shortest RS1 promoter construct 177/+32 into HEK293
cells. These cells do not endogenously express retinal
transcription factors and are therefore well suited to iden-
tify the speciﬁc transactivation potential of single heter-
ologously expressed retinal DNA-binding proteins. As
shown in Figure 2, CRX overexpression strongly transac-
tivates the RS1 proximal promoter construct in a dose-
dependent manner, resulting in an 80-fold induction
with the highest CRX dose. In contrast, OTX2, NR2E3
and NRL reveal no signiﬁcant eﬀects on the RS1 promo-
ter activity at all titrations analyzed (Figure 2).
Since NRL and NR2E3 are known to function in asso-
ciation with CRX on opsin gene promoters (40), we tested
the regulatory activity of both factors in combinatory
transient transfections with CRX. No signiﬁcant tran-
scriptional activity of NRL and NR2E3 could be detected
in any combination of NRL and NR2E3 individually
or combined with CRX in either HEK293 or Y79 cells
(data not shown).
CRX binds to the RS1 promoter, recruits CBP/P300/GCN5
and triggers histone H3 acetylation
To assess in vitro promoter associations with the putative
CRE/NR2E3/NRL binding sites, EMSAs were carried
out with nuclear extracts from Y79 retinoblastoma cells
and mouse retinal tissue in the presence of radiolabeled
oligonucleotide probes representative of the binding
motifs identiﬁed in the RS1 promoter (Figure 3A and
B). Both Y79 and murine retina express CRX, NR2E3
and NRL transcripts as identiﬁed by real-time qRT–
PCR (data not shown). BV-2 microglia cells were used
as speciﬁcity control since these cells are of myeloid
origin lacking endogenous CRX, NR2E3 and NRL
expression (data not shown). The three putative binding
sites for CRX (CRE1/2/3) were tested, but only probes
homologous to CRE1 and CRE3 sequences showed spe-
ciﬁc binding (Figure 3A and B). In contrast to CRE1 and
CRE3, only weak retardation bands were detectable with
the CRE2 probe (data not shown). The mobility shifts
from CRE1 and CRE3 could be blocked by both an
excess amount of wild-type unlabeled oligonucleotides
and an ABCA4 consensus sequence known to bind
CRX (38). As expected, mutant CRE competitors had
no eﬀect on the speciﬁc CRX binding. Addition of a poly-
clonal anti-CRX antibody did not produce a supershift,
but resulted in a speciﬁc displacement of CRX from its
target oligonucleotides. In addition to analyzing the
labeled probes with nuclear extracts, we tested the ability
of CRX to bind the promoter by using in vitro translated
CRX protein. As shown in Figure 3A and B, the in vitro
translated CRX shifted the radiolabeled CRE1 and CRE3
probes to the same positions as with the nuclear extract.
This result further conﬁrms the speciﬁcity of the CRX
binding and also suggests that CRX directly contacts
these consensus DNA elements in the RS1 promoter.
In accordance with the lack of transactivational or
repressional activities of NR2E3 and NRL in cotrans-
fection experiments, probes spanning the two putative
binding regions in the RS1 promoter showed no speciﬁc
binding to Y79 and mouse retinal nuclear extracts or
in vitro translated NR2E3 and NRL proteins (data not
shown).
To further analyze whether CRX, NR2E3 and NRL
bind to the proximal RS1 regulatory region in the natural
chromatin context, ChIP assays were performed with
wild-type or transcription factor-transfected Y79 cells.
For PCR analysis of IP samples, a speciﬁc primer set
was designed to amplify the 177/+130 RS1 promoter
region containing the consensus CRE/NR2E3/NRL sites.
CRX already associated with the proximal RS1 promoter
in untransfected Y79 cells and its in vivo binding activ-
ity markedly increased after overexpression (Figure 3C).
In contrast, neither NR2E3 nor NRL showed a speciﬁc
interaction with the RS1 promoter region in the untrans-
fected or transfected state (Figure 3C). This suggests
that CRX binds to the minimal RS1 promoter in vivo
and that the in silico predicted binding sites for NRL and
NR2E3 may not be functional.
We were furthermore interested in whether CRX
binding to the RS1 promoter recruits the histone acetyl
transferase (HAT) coactivators CBP, P300 and GCN5
with subsequent histone H3 (K9/K14) acetylation. These
coactivators have been recently shown to regulate CRX-
dependent transcription of several photoreceptor-speciﬁc
genes (34). ChIP assays were performed with wild-type
or CRX-transfected Y79 cells to simulate diﬀerent levels
of nuclear CRX protein. Antibodies against CRX, each of
the three coactivators, and AcH3 (K9/K14) were used for
immunoprecipitation. The IP samples were analyzed by
PCR ampliﬁcation of the 177/+130 RS1 promoter
region or the adjacent upstream promoter region 703/
530 lacking CRX-binding elements. The proximal red-
cone opsin promoter was used as positive control (34). As
shown in Figure 3D, CRX, the three HATs, and AcH3
Figure 2. RS1 promoter induction levels by CRX, OTX2, NR2E3
and NRL. HEK293 cells were cotransfected with the 177/+32 RS1
promoter–reporter construct and transcription factor expression vec-
tors. X-fold stimulation values were calculated by normalizing CRX,
OTX2, NRL and NR2E3 cotransfected cells to mock-vector transfec-
tions. CRX (black bars) speciﬁcally induces the RS1 promoter in a
dose-dependent manner. OTX2 (dark gray bars), NR2E3 (light gray
bars) and NRL (white bars) do not induce or suppress the RS1 pro-
moter. Each transfection was repeated three times with duplicate wells
analyzed. Error bars represent the standard deviation of the mean
from protein normalized luciferase activities.
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Figure 3. CRX, HATs and AcH3 are associated with the RS1 promoter region. (A and B) EMSAs with Y79, mouse retina, BV-2 microglia
nuclear extracts or in vitro translated transcription factors. The sequences used for EMSA analysis are shown below with the mutated nucleotides
underlined and conserved motifs printed in bold letters. Each gel was loaded with 5 mg of nuclear extracts or 4 ml of in vitro translated proteins,
as indicated. Arrows represent speciﬁc binding identiﬁable by shifted bands that were inhibited by excess unlabeled weight or consensus oligonu-
cleotides, but not by their mutant counterparts. Incubation with BV-2 microglia cells nuclear extract (M) did not result in a speciﬁc band shift.
Addition of 1 ml anti-CRX antibody did not produce a supershift, but speciﬁcally inhibited CRX binding to the oligonucleotide. Asterisks indicate
unspeciﬁc bands. (A) Interaction of RS1 CRE1 and (B) CRE3 with proteins in Y79 cells, mouse retina, BV-2 cells (M) and in vitro translated CRX
(IVT). (C) ChIP assays using wild-type Y79 cells or Y79 cells transfected with CRX, NR2E3 or NRL. Immunoprecipitation was carried out with
antibodies against CRX, NR2E3 or NRL. Input DNA served as positive control and IP with rabbit IgG antibody served as negative control. The
RS1 promoter fragment 177/+130 was analyzed for in vivo CRX, NR2E3 and NRL binding by ChIP–PCR. (D) ChIP assays using wild-type
or CRX-transfected Y79 cells with antibodies against CRX, CBP, P300, AcH3 and GCN5. Input DNA served as positive control and IP with rabbit
IgG antibody served as negative control. DNA fragments were analyzed by PCR for two diﬀerent RS1 promoter fragments and the red-cone
opsin promoter. The RS1 promoter fragment 177/+130 and the red-cone opsin control promoter displayed ChIP-PCR positive signals whereas the
RS1 promoter region 703/530 lacking CRX sites did not show speciﬁc CRX binding.
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were already associated with the proximal RS1 promoter
region in Y79 cells. CRX overexpression caused further
recruitment of CBP and P300 and increased AcH3 levels
as indicated by strong ChIP signals. GCN5 was also
bound to the RS1 promoter, albeit with lesser intensity.
The control red-cone opsin promoter was positive for
binding to CBP, P300, AcH3 and GCN5 especially in
the CRX-transfected state (Figure 3D), whereas PCR ana-
lysis of IgG-precipitated DNA did not yield detectable
PCR products. Furthermore, the RS1 upstream control
region 703/530 lacking CRX sites showed no in vivo
DNA–protein interactions. These results suggest that
CRX speciﬁcally binds to the RS1 promoter in vivo
with high aﬃnity, recruits CBP/P300/GCN5 and triggers
histone H3 acetylation required for RS1 gene expression.
CRE1 and CRE3 are essential for RS1 expression
We next determined the individual contribution of the
three CRE sites for RS1 expression. Four and six base
pair substitutions were introduced in each CRE sequence
motif eliminating the most conserved TAAT core sequence
(Figure 1A). We also generated double and triple mutants
based on the wild-type 177/+32 promoter construct.
CRE-mutant promoter plasmids were transfected into
two diﬀerent cell systems, Y79 cells (Figure 4A) and
CRX-overexpressing HEK293 cells (Figure 4B), and nor-
malized luciferase signals were quantiﬁed. Base pair
changes within either the ﬁrst (CRE1) or the third
(CRE3) site markedly diminished RS1 basal promoter
activity (Figure 4A) and reduced CRX-dependent induc-
tion (Figure 4B) by more than 50%, although residual
promoter activity was still present in these single mutant
constructs. When mutating the second CRX-binding ele-
ment (CRE2), constitutive RS1 promoter activity declined
to 60% (Figure 4A), but this construct was still CRX
inducible to the level of wild type (Figure 4B), suggesting
that CRX-mediated RS1 expression is independent of
CRX binding to CRE2. Double and triple mutants fur-
ther emphasized the importance of either CRE1 or CRE3
in stimulating RS1 expression. Mutations at both CRE1
and CRE3 sites reduced the basal promoter activity
below 30% and fully abolished luciferase induction as
shown by the CRE13 double and CRE123 triple mutant
(Figure 4A and B). In contrast, the constitutive RS1 pro-
moter strength and induction levels obtained with the
double mutants CRE12 or CRE23 were comparable to
single mutants CRE1 or CRE3, respectively (Figure 4A
and B). These results are in full agreement with the ﬁndings
from our CRE-EMSA experiments, emphasizing CRE1
and CRE3 as the critical cis-elements in CRX-dependent
RS1 promoter induction.
Figure 4. Delineation of the critical sequences required for CRX binding and RS1 promoter activity. Luciferase assays were performed with the RS1
wild-type promoter construct 177/+32, and CRE single-, double- and triple mutant promoters in Y79 cells (A) and HEK293 cells cotransfected
with CRX (B). The basal luciferase activity of the wild-type contruct 177/+32 (A) or the CRX-induction of the wild-type contruct 177/+32 was
set to 100%. Each transfection was repeated three times with duplicate wells analyzed. Error bars represent the standard deviation of the mean from
protein normalized luciferase activities.
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In vivoanalysis of functional cis-elements in theRS1promoter
To assess the possible relevance of our ﬁndings in vivo, we
examined the contribution of all three CRE motifs and the
putative NR2E3/NRL-binding sites for RS1-driven gene
expression in transgenic X. laevis. Transgenic tadpoles
were generated which express GFP driven by either
the X. laevis opsin promoter as control, the human RS1
promoter or mutated versions of the RS1 promoter.
Tadpoles that survived G418 selection were screened
for the presence of GFP in vivo. G418 selection eﬀectively
identiﬁes transgenic animals, as demonstrated by the high
incidence of GFP expression in G418-selected tadpoles
resulting from injection of the opsin promoter plasmid
(92%). Since the opsin promoter is very strong, assessing
GFP positive tadpoles is relatively easy. However, in
the RS1 promoter groups fewer GFP positive tadpoles
were observed and the GFP signal was markedly lower
(Table 1), indicating that the RS1 promoter is less
strong relative to the opsin promoter. The percentage
of GFP positives may be used as a crude measure of the
strength of the promoter constructs. Consequently, our
in vivo results suggest that mCRE1 and mCRE13 are
signiﬁcantly weaker promoters than WT, mCRE2,
mNRE and mNR2E3 (Table 1).
In order to conﬁrm these ﬁndings, confocal microscopy
of 14-day-old tadpole retinae was carried out. We ﬁrst
assessed GFP expression of the opsin positive promoter
compared with nontransgenic control retina (Figure 5A
and B) and a strong GFP signal was detected exclusively
in photoreceptors (Figures 5B and 6A). The wild-type
RS1 promoter drives GFP expression most strongly in
the photoreceptor layer (Figure 5C). This is consistent
with previous results in which retinoschisin mRNA was
detected in photoreceptors by in situ hybridization (6)
and suggests that the human RS1 promoter exhibits
normal activity in the X. laevis retina. GFP was also
present in the inner nuclear layer (likely bipolar cells)
albeit at lower levels (Figures 5C and 6B, asterisks). RS1
was previously detected on the exterior of bipolar cells (4)
but it was not clear whether the protein originated from
bipolar cells or was secreted by photoreceptors. The pres-
ent results provide the ﬁrst direct evidence that RS1 is
expressed by bipolar cells.
The vast majority of mCRE1 and mCRE13 retinae
exhibited no detectable GFP in any retinal cell layer
(Figure 5D and F). mNRE drives signiﬁcant photorecep-
tor expression but less bipolar expression (Figure 5G).
In contrast, mCRE2 and mNR2E3 promoters revealed
similar results when compared with the wild-type RS1
promoter in the retina (Figure 5E and H) and also drive
GFP expression in bipolar cells (Figure 6C and D).
DISCUSSION
In this study, we have identiﬁed cis-regulatory elements
required for in vitro and in vivo promoter activity of the
RS1 gene. This deﬁnes a core promoter downstream of an
ALU repeat that is suﬃcient to drive gene expression
in the retina. Most importantly, we identiﬁed CRX as
an important regulator of RS1 promoter activity and
showed that CRX acts via two evolutionarily conserved
binding sites, CRE1 and CRE3, which strongly stimulate
RS1 transcription. CRX binds to these sites with high
aﬃnity even in the absence of additional nuclear proteins.
Cooperative binding of CRX to both CRE1 and CRE3
seems to be required for full promoter induction, since
substitution of conserved nucleotides in either of the
two binding motifs causes a more than 50% reduction
in promoter activity and CRX-dependent transactivation.
Despite a strong binding prediction score and high inter-
species sequence conservation, the CRE2 motif appears
dispensable for CRX binding and only moderately aﬀects
full promoter activity.
Over the years, a complex regulatory network involving
CRX and associated factors like OTX2 has been described
(41). In this context, the presence of three CRE motifs
in the RS1 promoter is in full agreement with data from
the rhodopsin gene and its prototypic retina-speciﬁc pro-
moter. The rhodopsin proximal regulatory region harbors
at least three adjacent CRX sites required for strong
expression (24). Also, in contrast to the RS1 core pro-
moter, CRX seems to only moderately activate a rhodop-
sin luciferase reporter in the absence of NRL or NR2E3
binding to the basal promoter region (42). One explana-
tion for these obvious diﬀerences could be that Y79 reti-
noblastoma cells are not fully diﬀerentiated retinal cells,
such as photoreceptor cells or bipolar cells. Thus, Y79
may only serve as a model system for basal constitutive
expression of RS1. Moreover, HEK293 cells transfected
with expression plasmids for individual retina-speciﬁc
transcription factors may be more suitable for transacti-
vation experiments with CRX than with NRL or NR2E3.
Therefore, we cannot rule out that the signaling-depen-
dent expression or the developmental regulation of RS1
still requires a synergistic activity of CRX with other
retina-speciﬁc or general transcription factors.
The CRX-related homeobox gene OTX2 binds to
similar motifs, since OTX2 and its expression precedes
CRX early in neuronal development (43). We therefore
analyzed the ability of OTX2 to regulate the RS1 promo-
ter in cotransfection assays. In contrast to CRX, however,
OTX2 was not able to transactivate the RS1 gene, indicat-
ing that OTX2 is not a major factor in regulating the RS1
CRE motifs in vitro.
Table 1. Analysis of relative GFP expression of RS1 promoter
constructs
Promoter
construct
Number of
tadpoles
(i.e. surviving
G418 selection)
Percentage with
detectable GFP
at dpf14a (%)
Number examined by
confocal microscopy
XOP 13 92 3
WT 11 73 4
mCRE1 23 9 4
mCRE2 18 67 6
mCRE13 19 5 5
mNRE 15 53 6
mNR2E3 22 59 4
aAs determined by ﬂuorescent screening of tadpoles eyes in vivo.
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Our ChIP results in untransfected and CRX-transfected
Y79 cells showed that CRX binds to the proximal
RS1 promoter in its native chromatin conﬁguration. The
coactivators CBP, P300 and GCN5 were subsequently
recruited and histone H3 acetylation was detected in this
promoter region, indicative of active transcription. CBP,
P300 and GCB5 are critical components of retinal
development and are required for maintenance of photo-
receptor gene expression (34,40). Low AcH3 levels are
correlated with retinal diseases and transcriptional sup-
pression of opsin genes (44). Therefore, the low expression
levels of RS1 mRNA in the Crx/ retina (18) may be
at least partially related to compressed chromatin and
prevention of the basal transcription machinery to access
the RS1 promoter.
Further evidence for in vivo regulation of RS1 expression
by CRX comes from our transgenic X. laevis experiments.
The wild-type 177/+32 regulatory region consistently
drives GFP expression in the tadpole retina. The low
GFP signal found in CRE1 single- and CRE13 double
mutant transgenic X. laevis correlates well with the 60%
reduced promoter activity found in the in vitro transfec-
tion experiments, providing additional support that bind-
ing at both sites, CRE1 and CRE3, is crucial for RS1
promoter activity. Furthermore, localization of RS1 mini-
mal promoter-driven GFP in X. laevis is consistent with
ﬁndings of endogenous RS1 expression in human and
mice (4). In transgenic X. laevis, prominent RS1 expres-
sion is found in the photoreceptor layer and a cell-type
reminiscent of bipolar cells. In contrast, GFP expres-
sion was not seen in other cells types of the frog retina
including ganglion cells or glial cells, which have pre-
viously been suggested to express RS1 (16). In summary,
we conclude from our own ﬁndings as well as data in
Figure 5. In vivo analysis of RS1 promoter–GFP constructs. Confocal micrographs of transgenic X. laevis retinae expressing GFP (green) under the
control of various promoters. Cryosections were counterstained with wheat germ agglutinin (red) and Hoechst nuclear stain (blue). (A)
Nontransgenic control retina (NON-TG); (B) Xenopus opsin promoter (XOP); (C) RS1 promoter wild type (RS1-WT); (D) RS1 promoter with
mutated CRE1 (mCRE1); (E) RS1 promoter with mutated CRE2 (mCRE2); (F) RS1 promoter with mutated CRE1 and CRE3 (mCRE13); (G) RS1
promoter with mutated NRE (mNRE); (H) RS1 promoter with mutated NR2E3 (mNR2E3). GFP was not expressed in the nontransgenic retina but
was highly expressed in photoreceptors in the XOP retina. The wild-type RS1 promoter (NON-TG) drives GFP expression in photoreceptors albeit
at lower levels. Abolishing NRL and NR2E3 binding did not signiﬁcantly alter GFP expression (G and H). Mutating the CRE1 site (D and F)
reduced GFP expression to below detectable limits, but no obvious eﬀect resulted from mutating the CRE2 site (E). The GFP signals in panels A and
C-H are directly comparable as the same laser intensity and ampliﬁer setting were used, and identical image processing was applied. In panel B, the
ampliﬁer gain was reduced due to the intensity of the GFP signal. The inset shows an image acquired with settings equivalent to the other panels.
Photoreceptor outer segments (os), outer nuclear layer (onl), inner nuclear layer (inl) and inner plexiform layer (ipl). Scale bar, 50 mm.
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CRX-deﬁcient mice, which reveal strongly reduced RS1
transcript levels in retinal tissue (18,23) that CRX regulates
RS1 transcription in vivo.
Reduced RS1 mRNA levels in retinae from NRL-
deﬁcient mice (19,22), in addition to bioinformatic bind-
ing site predictions, has led us to address the contribution
of NRL and NR2E3 in regulating RS1 promoter activity.
However, no signiﬁcant inﬂuence of NRL and NR2E3
on the level of RS1 transcription in retinal cells could be
detected in vitro or in vivo. Since NRL and NR2E3 are
known to interact with a multitude of other transcrip-
tion factors (41), those partners might be absent in our
transfection assays. Nevertheless, we can exclude a direct
interaction of NR2E3 and NRL with the RS1 promoter
in vivo or with CRX as analyzed by our combination
cotransfection studies in the luciferase reporter assay.
Double cotransfections of these three transcription factors
were previously shown to synergistically activate several
rod phototransduction genes (26). In transgenic X. laevis,
mutant NRE and NR2E3 promoter constructs could drive
GFP expression to a level similar to wild type. This implies
that both binding sites are dispensable for basal induction
of the RS1 gene in the retina.
Overall, our data establish CRX as a crucial tran-
scriptional regulator of RS1 expression in the retina.
Additional in vivo models, such as transgenic mice will
help to further elucidate the CRX transcriptional network
driving gene expression from retinal promoters.
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